BR112018012579A2 - derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-di-hidro-5h-pirrolo[2,3-d]pirimidina e os respectivos derivados de (1h-indazol-3-il) como moduladores de cgmp para o tratamento de doenças cardiovasculares - Google Patents
derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-di-hidro-5h-pirrolo[2,3-d]pirimidina e os respectivos derivados de (1h-indazol-3-il) como moduladores de cgmp para o tratamento de doenças cardiovascularesInfo
- Publication number
- BR112018012579A2 BR112018012579A2 BR112018012579-2A BR112018012579A BR112018012579A2 BR 112018012579 A2 BR112018012579 A2 BR 112018012579A2 BR 112018012579 A BR112018012579 A BR 112018012579A BR 112018012579 A2 BR112018012579 A2 BR 112018012579A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- compounds
- pulmonary
- derivatives
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- -1 1h-indazol-3-yl Chemical group 0.000 title 1
- ATSCLNXOTFEDBO-UHFFFAOYSA-N 4-amino-2-(2H-pyrazolo[3,4-b]pyridin-3-yl)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical class NC=1C2=C(N=C(N=1)C1=NNC3=NC=CC=C31)NC(C2)=O ATSCLNXOTFEDBO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000003205 diastolic effect Effects 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2015/098251 | 2015-12-22 | ||
PCT/CN2015/098251 WO2017107052A1 (en) | 2015-12-22 | 2015-12-22 | Soluble guanylate cyclase stimulators |
PCT/US2016/067654 WO2017112617A1 (en) | 2015-12-22 | 2016-12-20 | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112018012579A2 true BR112018012579A2 (pt) | 2018-12-04 |
BR112018012579B1 BR112018012579B1 (pt) | 2023-10-24 |
BR112018012579B8 BR112018012579B8 (pt) | 2023-11-21 |
Family
ID=57758775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018012579A BR112018012579B8 (pt) | 2015-12-22 | 2016-12-20 | Composto modulador de cgmp, sua composição farmacêutica e seu uso |
Country Status (39)
Country | Link |
---|---|
US (2) | US10030027B2 (pt) |
EP (1) | EP3394067B1 (pt) |
JP (1) | JP6454448B2 (pt) |
KR (1) | KR102191312B1 (pt) |
CN (1) | CN108738320B (pt) |
AR (1) | AR107154A1 (pt) |
AU (1) | AU2016377364B2 (pt) |
BR (1) | BR112018012579B8 (pt) |
CA (1) | CA3009193C (pt) |
CL (1) | CL2018001671A1 (pt) |
CO (1) | CO2018006300A2 (pt) |
CR (1) | CR20180330A (pt) |
CY (1) | CY1123173T1 (pt) |
DK (1) | DK3394067T3 (pt) |
DO (1) | DOP2018000153A (pt) |
EA (1) | EA036445B1 (pt) |
EC (1) | ECSP18054606A (pt) |
ES (1) | ES2794654T3 (pt) |
HK (1) | HK1255028A1 (pt) |
HR (1) | HRP20200857T1 (pt) |
HU (1) | HUE049941T2 (pt) |
IL (1) | IL260020B (pt) |
LT (1) | LT3394067T (pt) |
ME (1) | ME03748B (pt) |
MX (2) | MX2018007728A (pt) |
MY (1) | MY194021A (pt) |
NI (1) | NI201800069A (pt) |
PE (1) | PE20181802A1 (pt) |
PH (1) | PH12018501342A1 (pt) |
PL (1) | PL3394067T3 (pt) |
PT (1) | PT3394067T (pt) |
RS (1) | RS60344B1 (pt) |
SG (1) | SG11201805272XA (pt) |
SI (1) | SI3394067T1 (pt) |
SV (1) | SV2018005715A (pt) |
TN (1) | TN2018000219A1 (pt) |
TW (1) | TWI724079B (pt) |
UA (1) | UA122264C2 (pt) |
WO (2) | WO2017107052A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
WO2016191335A1 (en) | 2015-05-28 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
EP3458063A4 (en) | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHODS OF USING TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR FIBROTIC DISORDERS |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3609883B1 (en) * | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
AU2020357514A1 (en) | 2019-09-30 | 2022-04-07 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
AU6691498A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
WO2000014095A1 (en) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
ATE362468T1 (de) | 2000-07-25 | 2007-06-15 | Merck & Co Inc | N-substituierte indole mit anwendung in der behandlung von diabetes |
EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
ES2342596T3 (es) | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
US7393960B2 (en) | 2002-08-29 | 2008-07-01 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
US7319170B2 (en) | 2003-01-17 | 2008-01-15 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzensulfonmide derivatives |
WO2009001836A1 (en) | 2007-06-28 | 2008-12-31 | Semiconductor Energy Laboratory Co., Ltd. | Manufacturing method of semiconductor device |
AU2008267724A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd | Substituted fused pyrimidines as antagonists of GPR105 activity |
CA2693214A1 (en) | 2007-07-19 | 2009-01-22 | Merck Sharp & Dohme Corp. | Beta carboline derivatives as antidiabetic compounds |
CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US9365574B2 (en) * | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
MX2013000198A (es) | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Pirimidinadas y triazinas condensadas y su uso. |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
ES2583086T3 (es) | 2011-04-21 | 2016-09-19 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con fluoroalquilo y su uso |
JP5976788B2 (ja) | 2011-05-06 | 2016-08-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用 |
KR20140050029A (ko) | 2011-07-06 | 2014-04-28 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 헤테로아릴-치환된 피라졸로피리딘 및 가용성 구아닐레이트 시클라제 자극제로서의 그의 용도 |
JP6054967B2 (ja) | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アネレート化ピリミジンおよびその使用 |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
PE20160201A1 (es) | 2013-07-10 | 2016-05-06 | Bayer Pharma AG | Bencil-1h-pirazol[3,4-b]piridinas y su uso |
WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015088886A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
JP2017527604A (ja) | 2014-09-17 | 2017-09-21 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激剤 |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
WO2016191335A1 (en) | 2015-05-28 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
BR112018015718A2 (pt) | 2016-02-01 | 2019-01-08 | Ironwood Pharmaceuticals Inc | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) |
-
2015
- 2015-12-22 WO PCT/CN2015/098251 patent/WO2017107052A1/en active Application Filing
-
2016
- 2016-12-20 PE PE2018001156A patent/PE20181802A1/es unknown
- 2016-12-20 SG SG11201805272XA patent/SG11201805272XA/en unknown
- 2016-12-20 CA CA3009193A patent/CA3009193C/en active Active
- 2016-12-20 MX MX2018007728A patent/MX2018007728A/es active IP Right Grant
- 2016-12-20 TW TW105142318A patent/TWI724079B/zh active
- 2016-12-20 EA EA201891303A patent/EA036445B1/ru not_active IP Right Cessation
- 2016-12-20 AR ARP160103930A patent/AR107154A1/es unknown
- 2016-12-20 UA UAA201808060A patent/UA122264C2/uk unknown
- 2016-12-20 ES ES16823455T patent/ES2794654T3/es active Active
- 2016-12-20 KR KR1020187020705A patent/KR102191312B1/ko active IP Right Grant
- 2016-12-20 CR CR20180330A patent/CR20180330A/es unknown
- 2016-12-20 EP EP16823455.7A patent/EP3394067B1/en active Active
- 2016-12-20 CN CN201680075365.8A patent/CN108738320B/zh active Active
- 2016-12-20 TN TNP/2018/000219A patent/TN2018000219A1/en unknown
- 2016-12-20 WO PCT/US2016/067654 patent/WO2017112617A1/en active Application Filing
- 2016-12-20 ME MEP-2020-103A patent/ME03748B/me unknown
- 2016-12-20 SI SI201630769T patent/SI3394067T1/sl unknown
- 2016-12-20 BR BR112018012579A patent/BR112018012579B8/pt active IP Right Grant
- 2016-12-20 LT LTEP16823455.7T patent/LT3394067T/lt unknown
- 2016-12-20 AU AU2016377364A patent/AU2016377364B2/en active Active
- 2016-12-20 HU HUE16823455A patent/HUE049941T2/hu unknown
- 2016-12-20 PL PL16823455T patent/PL3394067T3/pl unknown
- 2016-12-20 PT PT168234557T patent/PT3394067T/pt unknown
- 2016-12-20 US US15/384,429 patent/US10030027B2/en active Active
- 2016-12-20 DK DK16823455.7T patent/DK3394067T3/da active
- 2016-12-20 MY MYPI2018001031A patent/MY194021A/en unknown
- 2016-12-20 JP JP2018532431A patent/JP6454448B2/ja active Active
- 2016-12-20 RS RS20200620A patent/RS60344B1/sr unknown
-
2018
- 2018-06-13 NI NI201800069A patent/NI201800069A/es unknown
- 2018-06-13 IL IL260020A patent/IL260020B/en active IP Right Grant
- 2018-06-18 CO CONC2018/0006300A patent/CO2018006300A2/es unknown
- 2018-06-19 CL CL2018001671A patent/CL2018001671A1/es unknown
- 2018-06-19 SV SV2018005715A patent/SV2018005715A/es unknown
- 2018-06-21 PH PH12018501342A patent/PH12018501342A1/en unknown
- 2018-06-21 MX MX2020011080A patent/MX2020011080A/es unknown
- 2018-06-22 DO DO2018000153A patent/DOP2018000153A/es unknown
- 2018-06-27 US US16/019,964 patent/US10428076B2/en active Active
- 2018-07-19 EC ECSENADI201854606A patent/ECSP18054606A/es unknown
- 2018-11-06 HK HK18114149.1A patent/HK1255028A1/zh unknown
-
2020
- 2020-05-28 HR HRP20200857TT patent/HRP20200857T1/hr unknown
- 2020-06-16 CY CY20201100547T patent/CY1123173T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018012579A2 (pt) | derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-di-hidro-5h-pirrolo[2,3-d]pirimidina e os respectivos derivados de (1h-indazol-3-il) como moduladores de cgmp para o tratamento de doenças cardiovasculares | |
BR112018007161A2 (pt) | pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso | |
BR112018007145A2 (pt) | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso | |
BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
BR112012022868A2 (pt) | morfolinilquinazolinas | |
EA202090662A2 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
CR20120280A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
EP4249076A3 (en) | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor | |
BR112013026355A2 (pt) | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico | |
BR112012026907A2 (pt) | método para a preparação de uma microvesícula suportando tf tendo atividade pró-coagulante, microvesículas obstidas pelo dito metodo e seu uso, bem como composição farmacêutica e kit as compreendendo | |
BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
WO2014101295A3 (zh) | 一种詹纳斯激酶(jaks)抑制活性的异恶唑衍生物 | |
UY29127A1 (es) | Nuevos derivados de pirimidina y su uso | |
CO6551707A2 (es) | Procedimiento para la preparaciçon de {4.6-diamino-2[1-2(2-fluorobencil)-1h- pirazolo [3.4-b]piridin -3-il] pirimidin -5-il} carbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
PH12017500977A1 (en) | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | |
GEP20207095B (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
AR087164A1 (es) | Sales de di-aril-eteres aza-biciclicos y metodos para la elaboracion de las mismas o de sus precursores | |
WO2010085924A3 (en) | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | |
Tannenberg et al. | Lack Of Pdgf-B Retention Ameliorates Hypoxia-Induced Pulmonary Hypertension | |
Tlatelpa Romero et al. | Effect Of Inhaled Surfactant And Phosphatidylethanolamine On Bleomycin-Induced Lung Fibrosis In Mice | |
NZ621396A (en) | Substituted annellated pyrimidine and the use thereof | |
DOP2005000177A (es) | Nuevos derivados de pirimidina y su uso | |
ECSP12012358A (es) | Activadores de guanilato ciclasa soluble |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2755 DE 24/10/2023 QUANTO AO TITULO E AO ENDERECO. |